Literature DB >> 9814957

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.

J Tartaglia1, J L Excler, R El Habib, K Limbach, B Meignier, S Plotkin, M Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9814957

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  12 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Authors:  Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steve G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark J Mulligan; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

Review 3.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 6.  Novel directions in HIV-1 vaccines revealed from clinical trials.

Authors:  Jean-Louis Excler; Georgia D Tomaras; Nina D Russell
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 7.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

Authors:  Douglas H Smith; Peggy Winters-Digiacinto; Misrach Mitiku; Sara O'Rourke; Faruk Sinangil; Terri Wrin; David C Montefiori; Phillip W Berman
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

10.  Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Authors:  M J Schnell; H D Foley; C A Siler; J P McGettigan; B Dietzschold; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.